ProQinase, Mercachem Share Grant to Develop Epigenetics Platform | GenomeWeb

NEW YORK (GenomeWeb News) – ProQinase and Mercachem on Monday said they have been awarded €2.5 million ($3.2 million) to develop a new drug discovery platform targeting epigenetic enzyme families.

The three-year grant from the European Union's Eurostars program will be used to develop the platform, comprising novel biological and pharmacological assays, along with new chemical space libraries targeted against the most prominent epigenetic enzyme families, the partners said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.